As legislation that would force drug companies to stop using Chinese development and manufacturing contractors goes to a markup in the US House next week, the Biotechnology Innovation Organization has released an industry survey that found decoupling could be significantly disruptive.
BIO is hoping the results will help persuade lawmakers to provide a “substantial runway to begin and implement the decoupling...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?